BILL vs Tipalti for Life Sciences and Biotech Consulting Firms

A cost charged to a federally funded project has to be allowable, allocable, and reasonable under that funding source's rules, and demonstrating that months or years later depends entirely on how clearly the cost was tagged when the invoice was first entered. A consulting firm juggling several funding sources, direct client work, federal grants, foundation funding, at once needs every vendor invoice tagged to its correct project and funding source from day one, not reconstructed from memory during an audit that may happen well after the people involved have moved on to other projects.

For firms whose lab suppliers, CROs, and equipment vendors are US-based, which describes most firms serving domestic biotech and pharma clients, BILL's approval routing can be configured around project and funding-source codes, so a principal investigator or project lead approves costs tied to their own work. Its accounting sync keeps that tagging intact through to whatever reporting the firm has to produce for a client or a grant sponsor.

Firms that engage specialized international experts, certain regulatory consultants, specific research collaborators, or that source from overseas lab equipment and reagent vendors regularly, face the same cross-border payee and currency questions any global vendor network does. For a firm where that's a rare exception rather than a pattern, a standard international wire is usually simpler than adopting Tipalti's full onboarding infrastructure for one or two relationships that come up only occasionally.

A cost charged to the wrong funding source, or tagged generically instead of to the specific project it supported, creates real exposure on audit: the firm may have to return disallowed funds, and repeated errors can affect the firm's standing with a funding agency for future awards. Neither BILL nor Tipalti enforces grant compliance rules on its own, so a firm working with sponsored funding needs its own documented policy for what's allowable, with the AP tool's job being to make that tagging happen consistently at entry.

A principal investigator or technical lead is usually the right person to confirm a lab or CRO invoice reflects work actually performed, but final financial sign-off, particularly for anything charged against a grant, often needs a research administrator or finance lead with visibility across the firm's full funding portfolio. Configuring that two-step review, technical confirmation plus financial and compliance sign-off, protects against both a bad invoice and a compliance gap.

Say a research effort is partly funded by a federal grant and partly by direct client fees, with shared lab costs that need to be split proportionally between the two. If that split isn't documented at the point each vendor invoice is entered, reconstructing a defensible allocation later, especially under audit pressure, becomes a research administrator's worst task. Tagging the split at entry, with a documented allocation method the firm can explain consistently, is what actually protects the firm when a funder asks the question.

A small consulting practice with a handful of active projects doesn't need enterprise-grade infrastructure to get this right, it needs consistent habits enforced by whatever tool it's already using. BILL's approval routing, configured with clear project and funding-source tags required at entry, is usually sufficient scaffolding for a firm that isn't yet running a dozen simultaneous grant-funded engagements. The discipline matters more than the software, but the software should make that discipline the path of least resistance, not something a busy research lead has to remember to do correctly every time.

Build these habits into whichever tool the firm uses:

• Require project and funding-source tags at entry so every cost is traceable to the source it supported.
• Have the principal investigator or technical lead confirm that a lab or CRO invoice reflects work actually performed.
• Route final financial sign-off, especially for anything charged to a grant, through a research administrator or finance lead.
• Document how shared lab costs are split across funding sources at the moment each invoice is entered.